Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society
- PMID: 26501536
- PMCID: PMC4831582
- DOI: 10.1001/jama.2015.12783
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society
Erratum in
-
Incorrect Data in 2 Tables.JAMA. 2016 Apr 5;315(13):1406. doi: 10.1001/jama.2016.3404. JAMA. 2016. PMID: 27046378 No abstract available.
Abstract
Importance: Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality.
Objective: To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer.
Process: The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms.
Evidence synthesis: Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk.
Recommendations: The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).
Conclusions and relevance: These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.
Conflict of interest statement
Figures
Comment in
-
New Guidelines for Breast Cancer Screening in US Women.JAMA. 2015 Oct 20;314(15):1569-71. doi: 10.1001/jama.2015.13086. JAMA. 2015. PMID: 26501532 No abstract available.
-
Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms.JAMA Intern Med. 2015 Dec;175(12):1970-1. doi: 10.1001/jamainternmed.2015.6466. JAMA Intern Med. 2015. PMID: 26502319 Free PMC article.
-
Clinical Breast Examination and Breast Cancer Screening Guideline.JAMA. 2016 Apr 5;315(13):1403-4. doi: 10.1001/jama.2016.0686. JAMA. 2016. PMID: 27046372 No abstract available.
-
Clinical Breast Examination and Breast Cancer Screening Guideline--Reply.JAMA. 2016 Apr 5;315(13):1404. doi: 10.1001/jama.2016.0689. JAMA. 2016. PMID: 27046374 No abstract available.
Similar articles
-
Benefits and Harms of Breast Cancer Screening: A Systematic Review.JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
-
Screening for lung cancer: 2023 guideline update from the American Cancer Society.CA Cancer J Clin. 2024 Jan-Feb;74(1):50-81. doi: 10.3322/caac.21811. Epub 2023 Nov 1. CA Cancer J Clin. 2024. PMID: 37909877
-
Comparison of recommendations for screening mammography using CISNET models.Cancer. 2017 Oct 1;123(19):3673-3680. doi: 10.1002/cncr.30842. Epub 2017 Aug 21. Cancer. 2017. PMID: 28832983
-
Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1. Ont Health Technol Assess Ser. 2007. PMID: 23074501 Free PMC article.
-
A systematic assessment of benefits and risks to guide breast cancer screening decisions.JAMA. 2014 Apr 2;311(13):1327-35. doi: 10.1001/jama.2014.1398. JAMA. 2014. PMID: 24691608 Review.
Cited by
-
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.JAMA Netw Open. 2021 Mar 1;4(3):e210307. doi: 10.1001/jamanetworkopen.2021.0307. JAMA Netw Open. 2021. PMID: 33646313 Free PMC article.
-
Effect of Vitamin D Supplementation on Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Nutr. 2021 Apr 1;8:655727. doi: 10.3389/fnut.2021.655727. eCollection 2021. Front Nutr. 2021. PMID: 33869269 Free PMC article.
-
Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials.World J Clin Oncol. 2016 Aug 10;7(4):331-6. doi: 10.5306/wjco.v7.i4.331. World J Clin Oncol. 2016. PMID: 27579253 Free PMC article.
-
Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.PLoS One. 2016 Jun 9;11(6):e0155597. doi: 10.1371/journal.pone.0155597. eCollection 2016. PLoS One. 2016. PMID: 27280407 Free PMC article.
-
The Impact of Mammography Screening Guideline Changes Among Women Serving in the U.S. Military.Mil Med. 2020 Dec 30;185(11-12):e2088-e2096. doi: 10.1093/milmed/usaa176. Mil Med. 2020. PMID: 32803239 Free PMC article.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
-
- Howlander N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015.
-
- Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–1792. - PubMed
-
- Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP, 3rd, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53(3):141–169. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical